Let's see some viral log curves. HAART has no delivery issue with respect to ADME. For humans, we've reached the final frontier for HIV therapy - clearing the virus from the blood is easily achievable with one pill (Atripla) - we need something that will clear it from the reservoirs where the antivirals can't reach.
From Seymour's comments ("we don't work inside cells") and his comment at 8:00 where he notes "that's a whole other project" with respect to tackling herpes virus which is hidden latent in nerve cells, I suspect NNVC does not have the technology to tackle HIV. The facts are simple.
Don't forget there are almost no good preclinical assays for HIV. You really need to prove human efficacy. So without a lead candidate nomination with GMP/GLP pharmatox, etc followed by an IND submission - we're just guessing on the HIV results and their ability to translate to humans.
Sounds like it! But perhaps with the same dosage as the HAART cocktail the NNVC results are 25 times better. Hard to say from that blurb you referred to.
News 
Market Data 
Discover 
AI
